Budipine

	WikiDoc Resources for Budipine
Articles
Most recent articles on Budipine Most cited articles on Budipine Review articles on Budipine Articles on Budipine in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Budipine Images of Budipine Photos of Budipine Podcasts & MP3s on Budipine Videos on Budipine
Evidence Based Medicine
Cochrane Collaboration on Budipine Bandolier on Budipine TRIP on Budipine
Clinical Trials
Ongoing Trials on Budipine at Clinical Trials.gov Trial results on Budipine Clinical Trials on Budipine at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Budipine NICE Guidance on Budipine NHS PRODIGY Guidance FDA on Budipine CDC on Budipine
Books
Books on Budipine
News
Budipine in the news Be alerted to news on Budipine News trends on Budipine
Commentary
Blogs on Budipine
Definitions
Definitions of Budipine
Patient Resources / Community
Patient resources on Budipine Discussion groups on Budipine Patient Handouts on Budipine Directions to Hospitals Treating Budipine Risk calculators and risk factors for Budipine
Healthcare Provider Resources
Symptoms of Budipine Causes & Risk Factors for Budipine Diagnostic studies for Budipine Treatment of Budipine
Continuing Medical Education (CME)
CME Programs on Budipine
International
Budipine en Espanol Budipine en Francais
Business
Budipine in the Marketplace Patents on Budipine
Experimental / Informatics
List of terms related to Budipine

Budipine
Clinical data
AHFS/Drugs.com	International Drug Names
ATC code	N04BX03 (WHO) ;
Identifiers
	IUPAC name 1-tert-butyl-4,4-diphenylpiperidine;
CAS Number	57982-78-2 ;
PubChem CID	68778;
ChemSpider	62021 ;
UNII	L9026OPI2Z;
KEGG	D07306 ;
ChEMBL	ChEMBL334491 ;
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C21H27N
Molar mass	293.446 g/mol
3D model (JSmol)	Interactive image;
	SMILES c1(ccccc1)C3(c2ccccc2)CCN(C(C)(C)C)CC3;
	InChI InChI=1S/C21H27N/c1-20(2,3)22-16-14-21(15-17-22,18-10-6-4-7-11-18)19-12-8-5-9-13-19/h4-13H,14-17H2,1-3H3 ; Key:QIHLUZAFSSMXHQ-UHFFFAOYSA-N ;
(verify)

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Budipine is an antiparkinson agent.

Its mechanism of action is not well characterized.^[2] It is believed to be an NMDA receptor antagonist,^[3] however, promoting the synthesis of dopamine.^[4]

Because it provides additional benefits relative to existing treatments, it probably does not precisely mimic the mechanism of an existing known treatment.^[5]

References

↑ Martndale: The Complete Drug Reference, 35th Ed.
↑ Reichmann H (October 2006). "Budipine in Parkinson's tremor". J. Neurol. Sci. 248 (1–2): 53–5. doi:10.1016/j.jns.2006.05.039. PMID 16784759.
↑ J. Kornhuber, B. Herr, J. Thome, P. Riederer. "The antiparkinsonian drug budipine binds to NMDA and sigma receptors in postmortem human brain tissue". J.Neural Transm.Suppl. 46:127-133, 1995. PMID 8821048
↑ "umm.edu".
↑ Przuntek H, Bittkau S, Bliesath H; et al. (May 2002). "Budipine provides additional benefit in patients with Parkinson disease receiving a stable optimum dopaminergic drug regimen". Arch. Neurol. 59 (5): 803–6. doi:10.1001/archneur.59.5.803. PMID 12020263.

[1] Martndale: The Complete Drug Reference, 35th Ed.

[pmid16784759-2] Reichmann H (October 2006). "Budipine in Parkinson's tremor". J. Neurol. Sci. 248 (1–2): 53–5. doi:10.1016/j.jns.2006.05.039. PMID 16784759.

[3] J. Kornhuber, B. Herr, J. Thome, P. Riederer. "The antiparkinsonian drug budipine binds to NMDA and sigma receptors in postmortem human brain tissue". J.Neural Transm.Suppl. 46:127-133, 1995. PMID 8821048

[url-4] "umm.edu".

[pmid12020263-5] Przuntek H, Bittkau S, Bliesath H; et al. (May 2002). "Budipine provides additional benefit in patients with Parkinson disease receiving a stable optimum dopaminergic drug regimen". Arch. Neurol. 59 (5): 803–6. doi:10.1001/archneur.59.5.803. PMID 12020263.

[1]

[2]

[3]

[4]

[5]

Budipine

Overview

See also

References

Navigation menu